Linezolid
| Code | Size | Price |
|---|
| CDX-L0031-M025 | 25 mg | £157.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
N-[[(5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide; PNU-100766; U-100766
Appearance:
White to off-white powder.
CAS:
165800-03-3
EClass:
32160000
Form (Short):
solid
GHS Symbol:
GHS08
Handling Advice:
Protect from light and moisture.
Hazards:
H372
InChi:
InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1
InChiKey:
TYZROVQLWOKYKF-ZDUSSCGKSA-N
Long Description:
Chemical. CAS: 165800-03-3. Formula: C16H20FN3O4. MW: 337.35. Synthetic. Linezolid is a synthetic oxazolidinone antibiotic with activity against a wide range of Gram-positive bacteria. Displays potent antibacterial activity against a variety of multidrug-resistant gram-positive microbes in vitro and in vivo, including resistant strains of several species, such as methicillin-resistant S. aureus (MRSA), penicillin-resistant pneumococci, vancomycin-resistant enterococci, various anaerobic bacteria, and several mycobacteria and streptococci (MICs = 2-4mg/ml). Linezolid inhibits protein synthesis by binding to domain V of the 23S ribosomal RNA of the 50S subunit of bacterial ribosomes and preventing the formation of a functional 70S initiation complex, thus inhibiting bacterial mRNA translation. Linezolid is also a weak, reversible, nonselective inhibitor of monoamine oxidase.
MDL:
MFCD00937825
Molecular Formula:
C16H20FN3O4
Molecular Weight:
337.35
Package Type:
Vial
Precautions:
P260
Product Description:
Linezolid is a synthetic oxazolidinone antibiotic with activity against a wide range of Gram-positive bacteria. Displays potent antibacterial activity against a variety of multidrug-resistant gram-positive microbes in vitro and in vivo, including resistant strains of several species, such as methicillin-resistant S. aureus (MRSA), penicillin-resistant pneumococci, vancomycin-resistant enterococci, various anaerobic bacteria, and several mycobacteria and streptococci (MICs = 2-4mg/ml). Linezolid inhibits protein synthesis by binding to domain V of the 23S ribosomal RNA of the 50S subunit of bacterial ribosomes and preventing the formation of a functional 70S initiation complex, thus inhibiting bacterial mRNA translation. Linezolid is also a weak, reversible, nonselective inhibitor of monoamine oxidase.
Purity:
>98% (HPLC)
Signal Word:
Danger
SMILES:
CC(NC[C@H]1CN(C2=CC=C(N3CCOCC3)C(F)=C2)C(O1)=O)=O
Solubility Chemicals:
Soluble in DMSO (20mg/ml), DMF or chloroform. Slightly soluble in ethanol (1mg/ml) methanol. Insoluble in water.
Source / Host:
Synthetic
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
(1) C.W. Ford, et al.; Antimicrob. Agents Chemother. 40, 1508 (1996) | (2) S.J. Brickner, et al.; J. Med. Chem. 39, 673 (1996) | (3) R.N. Jones, et al.; Antimicrob. Agents Chemother. 40, 720 (1996) | (4) D. Clemett & A. Markham; Drugs 59, 815 (2000) (Review) | (5) H.B. Fung, et al.; Clin. Ther. 23, 356 (2001) (Review) | (6) C.W. Ford, et al.; Curr. Drug Targets Infect. Disord. 1, 181 (2001) (Review) | (7) D.M. Livermore; J. Antimicrob. Chemother. 51, ii9 (2003) (Review) | (8) S.J. Brickner, et al.; J. Med. Chem. 51, 1981 (2008) (Review) | (9) K.L. Leach, et al.; Ann. N. Y. Acad. Sci. 1222, 49 (2011) (Review) | (10) S. Ager & K. Gould; Infect. Drug Resist. 5, 87 (2012) | (11) B.A. Diep, et al.; Curr. Ther. Res. Clin. Exp. 73, 86 (2012) (Review) | (12) L.A. Pauchard, et al.; PLoS One 12, e0187187 (2017)